Canine protein-losing enteropathy (PLE) is a life-threatening syndrome with a pooled case fatality rate of 54.2%, making systematic workup and prompt, layered treatment essential. The most common underlying causes are chronic inflammatory enteropathy (CIE) and intestinal lymphangiectasia (IL), which frequently coexist — 76% of dogs with CIE and PLE have concurrent lacteal dilation on histopathology.Journal of Vete…
Diagnostic Workup
The hallmark laboratory finding is hypoalbuminemia, but the full biochemical picture guides both diagnosis and prognosis. Additional abnormalities include hypoglobulinemia, hypocholesterolemia, lymphopenia, hypocalcemia, and hypomagnesemia.Journal of Vete… At presentation to a veterinary nutrition service, mean albumin was 2.40 ± 0.64 g/dL, mean globulin was 2.43 ± 0.71 g/dL, and mean cholesterol was 129 ± 63 mg/dL.Journal of Vete… Serum albumin below 2.0 g/dL, hypocobalaminemia, and hypovitaminosis D are established negative prognostic indicators.Journal of Vete…+1 Vitamin D concentrations below the reference interval are common in PLE and are associated with worse outcome compared to dogs with normal vitamin D.Journal of Vete…
Cobalamin, vitamin D (25-hydroxyvitamin D), and C-reactive protein should be measured at baseline. Hypocobalaminemia correlates with serum albumin concentration and carries negative prognostic significance.Journal of Vete… Elevated C-reactive protein and decreased 25-hydroxyvitamin D both have independent prognostic value.Journal of Vete… Serum symmetric dimethylarginine (SDMA) may be elevated in PLE dogs due to increased protein turnover rather than renal disease, which is relevant when interpreting renal biomarkers in this population.Journal of Vete…
Hypercoagulability is a clinically important systemic complication documented in 45% of dogs with chronic enteropathy and was suspected as the cause of mortality in 10% of Yorkshire terriers with PLE — coagulation assessment is warranted in severely affected cases.Journal of Vete… Additional systemic complications to investigate include tryptophan deficiency and vitamin D3 deficiency.Veterinary Clin…
Intestinal biopsy — endoscopic or full-thickness — is recommended to determine the underlying cause and guide treatment selection. Histopathology identifies IL (lacteal dilation present in 46% of PLE cases), CIE subtype, and rules out alimentary lymphoma.Journal of Vete…+1 In dogs with severe hypoalbuminemia and high anesthetic risk, a therapeutic dietary trial may be initiated before biopsy.Journal of Vete… When biopsy is performed, ileal sampling should be included where feasible, as disease processes in the ileum can differ from the duodenum.Journal of Vete…
Negative prognostic indicators to assess at diagnosis include: serum albumin below 2.0 g/dL, hypocobalaminemia, hypovitaminosis D, elevated CCECAI score, low body weight, chronic vomiting, elevated blood urea nitrogen, small intestinal dilation, epaxial muscle loss, poor coat condition, elevated C-reactive protein, and high endoscopic scores.Journal of Vete…+1
Treatment
Dietary Therapy
Dietary management is the cornerstone of PLE treatment and should be initiated immediately, before or concurrent with other interventions. Dogs responsive to dietary treatment alone have improved clinical outcomes and longer survival times compared to dogs requiring immunosuppressive treatment.Journal of Vete…
For dogs with IL or concurrent IL and CIE, an ultra-low-fat (ULF) diet is the primary dietary intervention. Insufficient fat restriction is a recognized cause of treatment failure even in the absence of histologic lacteal dilation.Journal of Vete… ULF novel protein homemade diets were the most common diet trialed before referral (60%), fed at referral (57%), and recommended at veterinary nutrition service consultation (48%) in a cohort of 58 PLE dogs, with a median survival time of 1,661 days.Journal of Vete… For dogs with CIE without IL, a novel or hydrolyzed protein diet is appropriate.Journal of Vete…
For dogs with CE that have failed prior dietary and antibacterial trials, an extensively hydrolyzed protein diet (protein hydrolyzed to amino acids and oligopeptides) is an effective next step. Clinical success, defined as a ≥75% reduction in CIBDAI score, was achieved in 8/13 dogs at week 5 and 10/11 dogs at week 10 on a poultry feather hydrolysate extruded diet, without concurrent immunosuppressant treatment. Dogs with moderate or marked PLE were excluded from this trial.BMC Veterinary…
Assisted enteral feeding via tube should be considered in dogs with inflammatory PLE, particularly those receiving immunosuppressive treatment. Of 21 dogs with a feeding tube placed within 5 days of gastrointestinal biopsy, 76% had a positive outcome at 6 months versus 39% negative outcome overall in the cohort. Assisted enteral feeding was significantly associated with positive outcome in dogs receiving concurrent immunosuppressive treatment.Journal of Vete…
Immunosuppressive Therapy
Prednisolone is first-line immunosuppressive therapy for dogs with CIE/PLE, with approximately 50% of dogs achieving a positive clinicopathologic response. The standard dose used in pharmacokinetic evaluation is 1 mg/kg PO q24h.Journal of Vete… Glucocorticoid malabsorption is not a common cause of treatment failure — total prednisolone drug exposure and maximum serum concentrations do not differ between PLE dogs and healthy controls, and do not differ between short-term responders and non-responders within the PLE population.Journal of Vete… Switching to parenteral glucocorticoids for suspected malabsorption is therefore not supported by pharmacokinetic data.Journal of Vete…
Glucocorticoid monotherapy is appropriate in a subset of dogs; not all dogs require a second-line immunosuppressant (SLI) at initiation. In dogs treated with prednisolone alone, median time to serum albumin exceeding 20 g/L was 13 days, with median survival of 85 days (range 13–463 days). Dogs treated with prednisolone plus a SLI had a median survival of 166 days (range 8–390 days).Journal of Vete… Commonly used SLIs include azathioprine, cyclosporine, and chlorambucil.Journal of Vete…
Octreotide for Refractory IL
Octreotide, a somatostatin analogue, is an option for dogs with confirmed or suspected IL that are refractory to standard therapies. The median dose prescribed is 20 µg/kg SQ q24h (range 4–39 µg/kg SQ q24h), with median serum albumin at time of prescription of 1.7 g/dL (range 1.0–3.1 g/dL). Clinical sign improvement was noted in 6/12 (50%) dogs. Adverse effects occurred in 3/18 (17%) dogs, with discontinuation required in 1 dog.Journal of Vete…
Vitamin D Supplementation
Hypovitaminosis D is common in PLE dogs and is associated with worse outcome; cholecalciferol (vitamin D3) supplementation should be considered in affected dogs. Vitamin D deficiency in PLE is multifactorial, related to malabsorption, systemic inflammation, and direct enteric loss.Journal of Vete…
Summary Table
| Intervention | Dose / Protocol | Efficacy | Key Caveat |
|---|---|---|---|
| ULF novel protein diet | Homemade or commercial; fat restriction is critical | Median survival 1,661 days in VNS cohort; dietary-only responders have better outcomes than immunosuppression-treated dogs | Insufficient fat restriction causes treatment failure even without histologic lacteal dilation |
| Extensively hydrolyzed protein diet | Commercial extruded; fed for ≥10 weeks | 8/13 dogs achieved ≥75% CIBDAI reduction at week 5; 10/11 at week 10 | Excludes dogs with moderate-to-marked PLE; no concurrent immunosuppression used |
| Assisted enteral feeding | Tube placed within 5 days of biopsy | 76% positive outcome at 6 months in tube-fed dogs | Benefit most clearly demonstrated in dogs receiving concurrent immunosuppression |
| Prednisolone | 1 mg/kg PO q24h | ~50% positive clinicopathologic response | Malabsorption is not a common cause of failure; parenteral switch not supported |
| Prednisolone + SLI | Prednisolone + azathioprine, cyclosporine, or chlorambucil | Median survival 166 days | Not required in all dogs at initiation |
| Octreotide | 20 µg/kg SQ q24h (range 4–39 µg/kg) | 50% clinical sign improvement in refractory IL | Reserved for standard-therapy failures; 17% adverse effect rate |
| Cholecalciferol | Supplementation in hypovitaminosis D | Hypovitaminosis D associated with worse outcome; supplementation studied | Specific dosing protocol not established in the veterinary literature |
Would you like to go deeper on how to select between dietary-only management versus initiating immunosuppression at the time of diagnosis?